Deal finances Aethlon Hemopurifier, funds also used for debt reduction
By Devika Patel
Knoxville, Tenn., Nov. 26 – Aethlon Medical, Inc. said it has arranged a $3.3 million private placement of units. Roth Capital Partners is the agent.
The company will sell units of one common share and one fifth-share warrant at $0.30 per unit. Each whole warrant is exercisable at $0.30 for five years. The strike price is a 17.65% premium to the Nov. 26 closing share price of $0.34.
Settlement is expected Dec. 2.
Proceeds will be used for to advance the Aethlon Hemopurifier, for debt reduction and for general corporate purposes.
Aethlon, based in San Diego, develops therapeutic medical devices to treat viral infections.
| Issuer: | Aethlon Medical, Inc.
|
| Issue: | Units of one common share and a fifth-share warrant
|
| Amount: | $3.3 million
|
| Units: | 16,666,667
|
| Price: | $0.30
|
| Warrants: | One fifth-share warrant per unit
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $0.30
|
| Agent: | Roth Capital Partners
|
| Pricing date: | Nov. 26
|
| Settlement date: | Dec. 2
|
| Stock symbol: | OTCBB: AEMD
|
| Stock price: | $0.34 at close Nov. 26
|
| Market capitalization: | $163.67 million
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
